Company / R&D Expense
Immunocore Holdings plc R&D Expense History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$274.9M
FY2025
5-year range
$100.2M / $274.9M
FY2021-FY2025
Trend
+23.7%
vs FY2024
Sector context
#66 of 210
Health Care
What the data says
At $275M, Immunocore Holdings plc's r&d expense ranks #66 of 210 in the Health Care sector. R&D Expense has increased for 4 consecutive years, from $100M in FY2021 to $275M in FY2025.
Based on SEC 10-K filings.
$275M in FY2025 with a 3-year CAGR of +39.2%.
Improved from $164M to $275M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +39.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#66 of 210 in Health CareTop 31% of 210This company $274.9M Sector average $644.1M
▼
-57.3% below sector average
Key checks
Key Insights
- Immunocore Holdings plc's r&d expense has grown for 4 consecutive years.
- 3-year CAGR of +39.2%, indicating consistent growth.
- In FY2025, r&d expense increased 23.7% year-over-year.
- Ranks #66 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.32 (distress zone, below 1.8 threshold)
- Negative profit margin: -16.5%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $274.9M | +23.7% |
| FY2024 | $222.2M | +35.8% |
| FY2023 | $163.5M | +60.5% |
| FY2022 | $101.9M | +1.7% |
| FY2021 | $100.2M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026